← Leaderboards
Carolina Porras
Fundacion Inciensa
$11,742,990
Attributed
$11,742,990
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $7.7M · FY2022–25$10M$7.5M$5M$2.5M$0
'22
'23
'24
'25
Funding mix
By agency
NIH$11,742,990 · 1
By mechanism
N01$11,742,990 · 1
Top collaborators
No co-investigators on record.
Most similar at Fundacion Inciensa
Same institution · by research overlap
- Paula Gonzalez-Maya$38,145,031
- Rolando Herrero$14,003,389
- Paula Gonzalez$28,686,384
- Charles Sanchez$787,124
- Ana Cecilia Rodriguez$4,601,397
Others in their field
Other Rising Stars on “Costa Rica”
- David Clifford Flood · University Of Michigan At Ann Arbor$1,367,927
- Priyadarshini Kachroo · Brigham And Women'S Hospital$838,448
- Valerie Peters · Eastern Kentucky University$712,581
- Julissa Rojas-Sandoval · University Of Connecticut$499,631
- Max Chavarria · Bowie State University$460,025
- Maria Montez Rath · Stanford University$456,543
Research focus
Costa RicaVaccine TrialHuman Papilloma Virus VaccinationDoseCervical Cancer PreventionParticipantHuman Papilloma Virus VaccineHuman Papilloma Virus InfectionPreventProphylacticCostContractsPremalignantFollow-UpCervicalLesionGirlsMalignant Neoplasm Of Cervix UteriHuman Papillomavirus 16ImmunizationHuman Papilloma Virus-Related Malignant NeoplasmAreaMortalityRegimen
Grant awards (5)
FOLLOW-UP AND EXTENDED FOLLOW-UP OF PARTICIPANTS$120,000
N01 · FY2025 · CA · contact PI
FOLLOW-UP AND EXTENDED FOLLOW-UP OF PARTICIPANTS_ Cures funded$3,125,784
N01 · FY2024 · CA · contact PI
Laboratory testing of biospecimens collected from participants of the NCIâs HPV Vaccine studies.$608,967
N01 · FY2024 · CA · contact PI
FOLLOW-UP AND EXTENDED FOLLOW-UP OF PARTICIPANTS_ Cures funded$200,000
N01 · FY2023 · CA · contact PI
FOLLOW-UP AND EXTENDED FOLLOW-UP OF PARTICIPANTS_ Cures funded$7,688,239
N01 · FY2022 · CA · contact PI